May 11Innovative RNA Origami Anticoagulant Research Highlighted at MSE100 Centennial CelebrationOn Friday, April 5th, Thom LaBean showcased a poster titled "Multivalent, Aptamer-Decorated RNA Origami as Direct Thrombin Inhibitor with...
Apr 5Helixomer Inc. Secures $2 Million NIH Award for Development of Innovative Intravenous Anticoagulant and Reversal AgentRaleigh, NC – October, 2023 – Helixomer Inc., a pioneering entity in the realm of drug development, is pleased to announce the receipt of...
Apr 4David Harrell Appointed as New President and CEO of HelixomerHelixomer, Inc. announces the appointment of David Harrell as President and CEO, where he will lead the company's growth efforts,...
Dec 6, 2023WE RECENTLY PUBLISHED A PEER-REVIEWED RESEARCH ARTICLE ON OUR RNA ANTICOAGULANT TECHNOLOGYIn the prestigious scientific journal, Advanced Materials (Impact Factor=27.4) Nucleic acid aptamers selected for thrombin binding have...
Dec 6, 2023WE HAVE RECEIVED A CHANCELLOR’S INNOVATION FUND (CIF) AWARDThe funding has allowed us to pursue pre-clinical evaluation of our anticoagulant and reversal agent. "As a land-grant university, our...
Dec 5, 2023A DRAFT OF OUR NEXT PAPER HAS BEEN POSTED TO BIORXIV.The paper has also been submitted for peer-reviewed publication. Anticoagulants are commonly utilized during surgeries and to treat...